NASDAQ:HUMA

Humacyte Stock Insider Trading

Healthcare > Biotechnology

Buy HUMA

*Your capital is at risk

$0.84

-0.0851 (-9.21%)

At Close: Jun 22, 2026

Humacyte Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -74.51. In total, the insiders bought 11.3M and sold 10.43M HUMA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-74.51
● Buy	11.3M shares
● Sell	10.43M shares
82% Buy Activity Moderate Positive Correlation
Buy Signal Low Confidence Jun 11, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -74.51. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (82% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 21, 2025 Buy	Stock Options (right to buy) A-Award	Sander Dale A. CFO And Chief Corp. Deve. Off.	C-Suite Officer	283 101 Value: $1.29M
Jan 21, 2025 Buy	Stock Options (right to buy) A-Award	Niklason Laura E President, CEO And Director	CEO / President	1 130 311 Value: $5.15M
Jan 21, 2025 Buy	Stock Options (right to buy) A-Award	Dougan Brady W Director	Director	1 130 311 Value: $5.15M
Jan 21, 2025 Buy	Stock Options (right to buy) A-Award	Cao Yang Chief Regulatory Officer	Officer	283 101 Value: $1.29M
Jan 21, 2025 Buy	Stock Options (right to buy) A-Award	Scheessele William John Chief Commercial Officer	Officer	283 101 Value: $1.29M
Jan 21, 2025 Buy	Stock Options (right to buy) A-Award	Prichard Heather Ledbetter Chief Operating Officer	C-Suite Officer	283 101 Value: $1.29M
Dec 19, 2024 Buy	Stock Options (right to buy) A-Award	Niklason Laura E President, CEO And Director	CEO / President	525 Value: $5K
Dec 19, 2024 Buy	Stock Options (right to buy) A-Award	Sander Dale A. CFO And Chief Corp. Deve. Off.	C-Suite Officer	525 Value: $5K
Dec 19, 2024 Buy	Stock Options (right to buy) A-Award	Prichard Heather Ledbetter Chief Operating Officer	C-Suite Officer	525 Value: $5K
Dec 19, 2024 Buy	Stock Options (right to buy) A-Award	Dougan Brady W Director	Director	525 Value: $5K
Dec 19, 2024 Buy	Stock Options (right to buy) A-Award	Dougan Brady W Director	Director	525 Value: $5K
Dec 19, 2024 Buy	Stock Options (right to buy) A-Award	Prichard Heather Ledbetter Chief Operating Officer	C-Suite Officer	525 Value: $5K
Dec 19, 2024 Buy	Stock Options (right to buy) A-Award	Sander Dale A. CFO And Chief Corp. Deve. Off.	C-Suite Officer	525 Value: $5K
Dec 19, 2024 Buy	Stock Options (right to buy) A-Award	Niklason Laura E President, CEO And Director	CEO / President	525 Value: $5K
Dec 04, 2024 Buy	Common Stock P-Purchase	Constantino Michael T. Director	Director	4 600 Value: $20.2K
Dec 04, 2024 Buy	Common Stock P-Purchase	Constantino Michael T. Director	Director	4 600 Value: $20.2K
Nov 20, 2024 Sell	Common Stock S-Sale	Dougan Brady W Director	Director	261 369 Value: $1.15M
Nov 20, 2024 Sell	Common Stock S-Sale	Niklason Laura E President, CEO And Director	CEO / President	261 369 Value: $1.15M
Nov 19, 2024 Buy	Common Stock P-Purchase	Niklason Laura E President, CEO And Director	CEO / President	1 797 Value: $8K
Nov 19, 2024 Buy	Common Stock P-Purchase	Dougan Brady W Director	Director	1 797 Value: $8K
Nov 19, 2024 Buy	Common Stock P-Purchase	Dougan Brady W Director	Director	1 797 Value: $8K
Nov 19, 2024 Buy	Common Stock P-Purchase	Niklason Laura E President, CEO And Director	CEO / President	1 797 Value: $8K
Nov 19, 2024 Sell	Common Stock S-Sale	Niklason Laura E President, CEO And Director	CEO / President	427 459 Value: $1.86M
Nov 19, 2024 Sell	Common Stock S-Sale	Dougan Brady W Director	Director	427 459 Value: $1.86M
Aug 26, 2021 Buy	Common Stock J-Other	Fresenius Medical Care Holdings Inc /ny/ Insider	Other	0 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT HUMACYTE, INC.

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without i...

Read Full Profile Here